Clinical authority, conflicts, evidence review, privacy, incidents, complaints, partner diligence, and patient handover require documented ownership and audit.
The founder’s medical role, company ownership, referral relationships, remuneration, and any hospital interest require clear separation and disclosure.
A medical director and appropriately scoped specialty advisers control pathway policy, redirections, treatment classification, and clinical-content review. Oncology remains the priority programme. Commercial staff cannot override a safety stop.
Review reaches the exact legal entity and site: licence, named team, treatment authority, procedure or product experience, emergency capability, consent, data, billing, refunds, incidents, outcomes, and handover.
Patients should normally pay hospitals directly. Navigation fees are disclosed. Referral commissions linked to treatment value, hidden mark-ups, gifts, and target-driven clinical decisions are prohibited.
The public form accepts no full medical record. Detailed records require identity, consent, secure upload, role-based access, audit logging, retention rules, incident response, and appropriate cross-border safeguards.
After a minimal enquiry is stored, a redacted operational alert may be sent through the company owner's configured notification channel. It contains the reference, country or region, planning urgency, record-availability status, language, and secure website link. It excludes the diagnosis summary, age group, filenames, uploaded records, policy details, and other clinical information.
Patients can raise service, billing, privacy, language, conflict, or safety concerns. Material content errors are corrected transparently, and serious incidents enter a quality review process.
Every clinical article identifies its accountable author and reviewer, evidence cutoff, last review, next review, treatment category, regulatory source, principal evidence, material harms, alternatives, and jurisdictions. Regulator and official professional sources take priority, followed by peer-reviewed literature and clearly labelled provider information. Material corrections are dated and explained. Product and hospital claims expire after six months unless renewed; trial availability and price evidence expire sooner.
Content is reviewed against current regulators, professional standards, peer-reviewed literature, and documented provider information.
The first enquiry intentionally asks for very little information.